AIMS: The objective is to estimate cost, net social cost and cost-effectiveness in a clinical trial of extended buprenorphine-naloxone (BUP) treatment versus brief detoxification treatment in opioid-dependent youth. DESIGN: Economic evaluation of a clinical trial conducted at six community out-patient treatment programs from July 2003 to December 2006, who were randomized to 12 weeks of BUP or a 14-day taper (DETOX). BUP patients were prescribed up to 24 mg per day for 9 weeks and then tapered to zero at the end of week 12. DETOX patients were prescribed up to 14 mg per day and then tapered to zero on day 14. All were offered twice-weekly drug counseling. PARTICIPANTS: 152 patients aged 15-21 years. MEASUREMENTS: Data were collected prospectively during the 12-week treatment and at follow-up interviews at months 6, 9 and 12. FINDINGS: The 12-week out-patient study treatment cost was $1514 (P < 0.001) higher for BUP relative to DETOX. One-year total direct medical cost was only $83 higher for BUP (P = 0.97). The cost-effectiveness ratio of BUP relative to DETOX was $1376 in terms of 1-year direct medical cost per quality-adjusted life year (QALY) and $25,049 in terms of out-patient treatment program cost per QALY. The acceptability curve suggests that the cost-effectiveness ratio of BUP relative to DETOX has an 86% chance of being accepted as cost-effective for a threshold of $100,000 per QALY. CONCLUSIONS: Extended BUP treatment relative to brief detoxification is cost effective in the US health-care system for the outpatient treatment of opioid-dependent youth.
RCT Entities:
AIMS: The objective is to estimate cost, net social cost and cost-effectiveness in a clinical trial of extended buprenorphine-naloxone (BUP) treatment versus brief detoxification treatment in opioid-dependent youth. DESIGN: Economic evaluation of a clinical trial conducted at six community out-patient treatment programs from July 2003 to December 2006, who were randomized to 12 weeks of BUP or a 14-day taper (DETOX). BUPpatients were prescribed up to 24 mg per day for 9 weeks and then tapered to zero at the end of week 12. DETOX patients were prescribed up to 14 mg per day and then tapered to zero on day 14. All were offered twice-weekly drug counseling. PARTICIPANTS: 152 patients aged 15-21 years. MEASUREMENTS: Data were collected prospectively during the 12-week treatment and at follow-up interviews at months 6, 9 and 12. FINDINGS: The 12-week out-patient study treatment cost was $1514 (P < 0.001) higher for BUP relative to DETOX. One-year total direct medical cost was only $83 higher for BUP (P = 0.97). The cost-effectiveness ratio of BUP relative to DETOX was $1376 in terms of 1-year direct medical cost per quality-adjusted life year (QALY) and $25,049 in terms of out-patient treatment program cost per QALY. The acceptability curve suggests that the cost-effectiveness ratio of BUP relative to DETOX has an 86% chance of being accepted as cost-effective for a threshold of $100,000 per QALY. CONCLUSIONS: Extended BUP treatment relative to brief detoxification is cost effective in the US health-care system for the outpatient treatment of opioid-dependent youth.
Authors: Susan L Ettner; David Huang; Elizabeth Evans; Danielle Rose Ash; Mary Hardy; Mickel Jourabchi; Yih-Ing Hser Journal: Health Serv Res Date: 2006-02 Impact factor: 3.402
Authors: Kathryn E McCollister; Michael T French; Ashli J Sheidow; Scott W Henggeler; Colleen A Halliday-Boykins Journal: J Behav Health Serv Res Date: 2008-01-03 Impact factor: 1.505
Authors: George E Woody; Sabrina A Poole; Geetha Subramaniam; Karen Dugosh; Michael Bogenschutz; Patrick Abbott; Ashwin Patkar; Mark Publicker; Karen McCain; Jennifer Sharpe Potter; Robert Forman; Victoria Vetter; Laura McNicholas; Jack Blaine; Kevin G Lynch; Paul Fudala Journal: JAMA Date: 2008-11-05 Impact factor: 56.272
Authors: Christopher M Doran; Marian Shanahan; Richard P Mattick; Robert Ali; Jason White; James Bell Journal: Drug Alcohol Depend Date: 2003-09-10 Impact factor: 4.492
Authors: Jeremy W Bray; Brandon Aden; Ashley A Eggman; Leah Hellerstein; Eve Wittenberg; Bohdan Nosyk; Judy C Stribling; Bruce R Schackman Journal: J Subst Abuse Treat Date: 2017-02-10
Authors: Bruce R Schackman; Jared A Leff; Daniel Polsky; Brent A Moore; David A Fiellin Journal: J Gen Intern Med Date: 2012-01-04 Impact factor: 5.128
Authors: Traci R Rieckmann; Nicholas Gideonse; Amanda Risser; Jennifer E DeVoe; Amanda J Abraham Journal: J Behav Health Serv Res Date: 2017-07 Impact factor: 1.505
Authors: Susan H Busch; David A Fiellin; Marek C Chawarski; Patricia H Owens; Michael V Pantalon; Kathryn Hawk; Steven L Bernstein; Patrick G O'Connor; Gail D'Onofrio Journal: Addiction Date: 2017-08-16 Impact factor: 6.526
Authors: Federico E Vaca; James Dziura; Fuad Abujarad; Michael V Pantalon; Allen Hsiao; Craig A Field; Gail D'Onofrio Journal: Contemp Clin Trials Date: 2020-09-16 Impact factor: 2.226
Authors: Kathryn E McCollister; Michael T French; Derek M Freitas; Michael L Dennis; Christy K Scott; Rodney R Funk Journal: Addiction Date: 2013-10-09 Impact factor: 6.526